India Pharma Outlook Team | Friday, 26 June 2026
The Centre is planning a major regulatory change that could make drug import license procedures easier for pharmaceutical companies involved in early-stage research.
The proposed move aims to remove the requirement for a drug import license when importing drugs meant only for preclinical testing, helping companies begin research faster with fewer regulatory hurdles.
The change is expected to come through amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, and is part of the government's broader effort to improve the ease of doing business in India's pharmaceutical sector.
The proposal is expected to benefit pharmaceutical companies, contract research organizations (CROs), and research institutions that import small quantities of drugs for laboratory studies before they enter human clinical trials.
Since these drugs are not intended for commercial sale or patient use, the government believes removing the licensing requirement can reduce unnecessary paperwork without affecting regulatory oversight.
At present, companies importing drugs for preclinical studies are required to obtain a test license from the Central Drugs Standard Control Organization (CDSCO). This process often adds time to research projects due to documentation and approval requirements.
If the proposed amendment is approved:
The proposal only applies to drugs imported for preclinical research. Regulatory approvals for clinical trials, manufacturing, and commercial use will continue under existing provisions.
Also Read: How Portfolio Strategy Drives Profitability in Pharma Markets
The latest proposal follows a series of reforms introduced by the Centre to simplify India's drug regulatory framework and promote pharmaceutical innovation.
Some of the recent measures include:
Together, these measures are aimed at making India's regulatory environment more efficient while maintaining safety standards.
The proposed amendment could offer significant advantages to the pharmaceutical and biotechnology sectors by reducing administrative delays during the earliest stages of research.
Key benefits include:
Industry experts believe that simplifying import procedures for research materials could make India a more attractive destination for global drug development projects. By allowing researchers to access investigational products without an additional licensing step, companies may be able to move promising candidates into the next phase of development more efficiently.
While the proposal is expected to ease compliance for early-stage research, regulatory scrutiny over clinical trials, manufacturing quality, and patient safety will remain unchanged. The government is focusing on removing procedural barriers where risks are relatively low while continuing strict oversight of activities that directly impact public health.
If implemented, the amendment to the NDCT Rules, 2019 could become another important step in India's ongoing efforts to modernize its pharmaceutical regulatory framework and accelerate research without compromising safety.
.jpg)
